Investigating Targeted CD3 Activation_990x120
watch on demand (2)
If you have already registered, follow this link and enter your e-mail address into the "Already Registered?" field to view the webinar.

Event Overview

Immune checkpoint inhibitors promote anti-tumor immune responses by enhancing T-cell activity. Measuring the pharmacodynamic effects of these drug types presents a challenge as both the immune and cancer cell populations must be separated and assessed individually. Using a quantitative multiplex immunofluorescence assay (mIF) allows for in depth-cell phenotype characterization and spatial context. Researchers at Frederick National Laboratory for Cancer Research developed a robust mIF assay with InSituPlex® technology to better investigate T-cell activation states within the tumor microenvironment and across multiple patient tumor biopsies.

In this webinar, Dr. Kristin Fino of the Frederick National Laboratory will present the obstacles associated with developing biomarker strategies and a multiplex immunofluorescence solution that improved the assessment of tumor-immune interactions.

This webinar is sponsored by Ultivue Inc.

Topics to be Covered

  • Introduction to the InSItuPlex® technology
  • Development of a multiplex panel for the quantitative assessment of T-cell activation in relation to tumor cells
  • Analyzing biomarker and cell phenotype trends across tumor types
Friday, November 1, 2019
2:30 - 4:00 PM Eastern Time


Sean Downing, PhD, MBA
Director, Customer Engagement

Kristin Fino, PhD
Leidos Biomedical NCI Frederick


Register Now

Investigating Targeted CD8 Activation via Immune Checkpoint Inhibition with an Advanced Multiplex Immunofluorescence Assay

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with Ultivue, the sponsoring vendor of this webinar. Our sponsor may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.